Invion Ltd Market Cap ($2.06 Million)
Market Cap & Net Worth: Invion Ltd (IVX)
Invion Ltd market cap. Invion Ltd (AU:IVX) has a market capitalization of $2.06 Million (AU$2.91 Million) as of November 7, 2026. Listed on the AU stock exchange, this Australia-based company holds position #29988 globally and #1728 in its home market, demonstrating a 3.03% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Invion Ltd's stock price AU$0.03 by its total outstanding shares 85647255 (85.65 Million). Also see cash efficiency ratio of Invion Ltd for how efficiently the company converts equity into cash flow.
Invion Ltd Market Cap History (2015–2026)
Invion Ltd market cap history from 2015 to 2026. Data shows change from $28.71 Million to $2.06 Million (-26.00% CAGR). Check Invion Ltd stock quote for real-time trading data and today's change.
Invion Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Invion Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Invion Ltd growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
4.59x
Invion Ltd's market cap is 4.59 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $9.57 Million | $139.10K | -$4.45 Million | 68.79x | N/A |
| 2018 | $109.08 Million | $737.71K | -$926.51K | 147.86x | N/A |
| 2019 | $78.78 Million | $3.88 Million | -$2.55 Million | 20.29x | N/A |
| 2020 | $60.60 Million | $3.48 Million | -$953.89K | 17.43x | N/A |
| 2021 | $127.26 Million | $2.33 Million | -$1.48 Million | 54.62x | N/A |
| 2022 | $54.54 Million | $3.29 Million | -$2.24 Million | 16.57x | N/A |
| 2023 | $30.30 Million | $4.10 Million | -$1.61 Million | 7.38x | N/A |
| 2024 | $16.97 Million | $3.69 Million | -$5.63 Million | 4.59x | N/A |
Competitor Companies of IVX by Market Capitalization
Companies near Invion Ltd in the global market cap rankings as of November 7, 2026. Also see Invion Ltd total assets for a full breakdown of the balance sheet.
Key companies related to Invion Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #530 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #567 globally with a market cap of $47.07 Billion USD ( CN¥321.69 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #609 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #530 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.61 |
| #567 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $47.07 Billion | CN¥50.43 |
| #609 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.80 |
Market Capitalization of Invion Ltd (2015–2026)
Market capitalization of Invion Ltd from 2015 to today. Between 2015 and today, Invion Ltd's market cap moved from $28.71 Million to $ 2.06 Million, with a yearly change of -26.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$2.06 Million | -63.44% |
| 2025 | AU$5.64 Million | -66.79% |
| 2024 | AU$16.97 Million | -44.00% |
| 2023 | AU$30.30 Million | -44.44% |
| 2022 | AU$54.54 Million | -57.14% |
| 2021 | AU$127.26 Million | +110.00% |
| 2020 | AU$60.60 Million | -23.08% |
| 2019 | AU$78.78 Million | -27.78% |
| 2018 | AU$109.08 Million | +279.91% |
| 2017 | AU$28.71 Million | +200.06% |
| 2016 | AU$9.57 Million | -66.67% |
| 2015 | AU$28.71 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Invion Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.06 Million USD |
| MoneyControl | $2.06 Million USD |
| MarketWatch | $2.06 Million USD |
| marketcap.company | $2.06 Million USD |
| Reuters | $2.06 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Invion Ltd
Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme, lung, and ovarian cancers; and human papilloma virus. It is also in… Read more